The facility will be designed, commissioned and operated by specialist staff from UK Biocentre (the service organization established as part of the pioneering UK Biobank project) that already provides similar services to the academic community.
"Working with the
"We are proud to be selected as a partner to support the
Brooks Life Science Systems will commission eight automated storage systems to be built on its recently released automated storage platform and will provide five years of services, representing a total value of approximately
About UK Biocentre
The skills and knowledge gained in developing UK Biobank have been used to establish UK Biocentre, a wholly-owned UK Biobank subsidiary geared to helping other pioneering health studies. UK Biobank has become a world-leader in biological sample management, as well as the setting up of information systems required to run large, population-based studies. UK Biocentre makes it easier for this knowledge to be passed on to other researchers and organizations, who can also use its state-of-the-art facilities for their own samples – avoiding the need to, and cost of, recreating the system elsewhere.
For further information, please e-mail info@ukbiocentre.com or visit the UK Biocentre website
About
From the genetic and molecular basis of disease to the latest advances in neuroscience,
About
Brooks is a leading worldwide provider of automation and cryogenic solutions for multiple markets including semiconductor manufacturing and life sciences. Brooks' technologies, engineering competencies and global service capabilities provide customers speed to market and ensure high uptime and rapid response, which equate to superior value in their mission-critical controlled environments. Since 1978, Brooks has been a leading partner to the global semiconductor manufacturing market and, through product development initiatives and strategic business acquisitions, has expanded offerings to meet the needs of customers in the life sciences industry, analytical & research markets and clean energy solutions. Brooks is headquartered in
"Safe Harbor Statement" under Section 21E of the Securities Exchange Act of 1934
Some statements in this release are forward-looking statements made under Section 21E of the Securities Exchange Act of 1934. These statements are neither promises nor guarantees but involve risks and uncertainties, both known and unknown, that could cause Brooks' financial and business results to differ materially from our expectations. They are based on the facts known to management at the time they are made. These forward-looking statements include statements regarding the success of the UK Biobank's initiatives, or the timeline of installation of our automated storage systems at the UK Biobank. Factors that could cause results to differ from our expectations include the following: volatility of the industries the Company serves, particularly the semiconductor industry; our possible inability to meet demand for our products due to difficulties in obtaining components and materials from our suppliers in required quantities and of required quality; the inability of customers to make payments to us when due; the timing and effectiveness of cost reduction and cost control measures; price competition; disputes concerning intellectual property; continuing uncertainties in global political and economic conditions, and other factors and other risks that we have described in our filings with the
CONTACT: Brooks Automation Contact:John Mills Senior Managing DirectorICR, LLC 310.954.1105 john.mills@icrinc.com
Brooks Automation, Inc.